#Italy #Healthcare Innovation #Rome #Haier Biomedical #European Summit

Haier Biomedical's European Partner Summit in Rome

On March 11, 2026, Haier Biomedical held its European Partner Summit in Rome, under the tagline "Joint Progress - Sharing the Future of Biomedical Innovation." This gathering brought together 37 regional partners and industry leaders from 23 European countries. The objective was to outline the company's long-term commitment to Europe, amid the unveiling of its expanded laboratory solutions portfolio, signaling a strategic transformation of the brand's offerings.

Commitment to Europe

Enrique Wang, the Global Market Director at Haier Biomedical, reaffirmed the company's vision, indicating that by 2027, over 50% of its global revenue is expected to come from international markets, with more than half of revenue sources moving beyond refrigeration by 2028. He emphasized that Europe remains a strategic focus in the company's globalization plan. The principle of localizing operations "In Europe, for Europe" stands firm, aiming to provide products, services, and support tailored to regional regulatory standards, customer expectations, and application needs.

European Strategy for 2026

Semir Selimovic, Director of Haier Biomedical Europe for Northern, Central, and Eastern Europe, delineated the 2026 European strategy. This strategy highlights the ongoing investment in local sales, service capabilities, and product knowledge, enhancing responsiveness and operational delivery in key markets. Europe has emerged as one of the fastest-growing regions for Haier Biomedical, reflected in the expansion of local teams and an ever-growing product portfolio.

Introduction of Innovative Products

Among the new offerings introduced at the summit was the XJ-III plasma apheresis system, which achieved EU MDR certification—a significant milestone towards meeting stringent regulatory requirements in Europe. This advancement solidifies Haier Biomedical's positioning in blood and plasma technology. Across Europe, products such as CO2 incubators, centrifuges, biosafety cabinets, and ultra-low temperature storage systems have gained market share, bolstered by energy-efficient technologies and compliance with regional certification standards.

Automation and Smart Blood Management

Daniele Pericolini, European Solutions Specialist at Haier Biomedical, presented the company’s strategic direction towards future growth through lab automation and smart blood management systems. The company’s biobanking solutions integrate ultra-low temperature storage using RFID technology, modular automation platforms, and liquid nitrogen systems, enhancing sample traceability and operational efficiency. By addressing challenges related to sample integrity, temperature monitoring, and high-density storage, Haier Biomedical has solidified its presence in the European market, where demand for advanced biobanking infrastructure is on the rise.

The U-Blood smart blood management system represents a shift from traditional cold storage to real-time blood supply chain management. Designed to reduce waste, improve traceability, and support around-the-clock transfusion processes, this solution aligns with Europe's increased focus on safety, digitization, and zero-waste health initiatives.

Success Stories from Partners

During the summit, success stories from four European partners from Germany, Slovenia, France, and Denmark were showcased, highlighting strong local acceptance of Haier Biomedical's solutions. A long-term partner in France presented a jointly developed biosafety cabinet tailored to meet French standards, with over 230 units deployed across more than 100 clients. Danish partners shared successes in ultra-low temperature storage achieved through public tenders and continuous expansion into additional product categories. In Slovenia, large pharmaceutical installations have enhanced the company’s capability to manage complex multi-unit projects. Central European partners underscored reliability, regulatory compliance, and after-sales support as key differentiators.

Notable Growth in International Markets

Haier Biomedical’s expansion in Europe is supported by solid financial results. In 2025, the company reported revenues exceeding RMB 2.3 billion, with international revenue reaching RMB 840 million, accounting for over 36% of total revenue—a reflection of its ongoing global expansion. The European segment recorded double-digit growth, significantly contributing to the overall increase in international revenue. AI and automation-based solutions constituted approximately 15% of total revenue in 2025, signaling an acceleration in technology-driven transformation. These results indicate a shift from exporting equipment towards providing localized solutions backed by regional teams and certifications across more than 18 countries.

Conclusion and Future Commitments

Concluding the European Partner Summit, Haier Biomedical reaffirmed its commitment to strengthening local operations, broadening automation solutions for the life science sector, and supporting collaborative growth with partners. By merging global innovative capacities with local execution in Europe, Haier Biomedical aims to further enhance its status as a trusted provider of life science solutions in 2026 and beyond.

For further information, visit Haier Biomedical.